Volume 2.03 | Jan 28

Mammary Cell News 2.03, January 28, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Hormonally Up-Regulated Neu-Associated Kinase (HUNK) Suppresses Metastasis of Basal Type Breast Cancers by Disrupting the Interaction Between PP2A and Cofilin-1
Study shows that HUNK is dramatically down-regulated in tumor samples and cell lines derived from basal breast cancers. [PNAS]

ALDEFLUORBreastCancer_645x110_v02



SCIENCE NEWS

Boston University School of Medicine Researchers Discover Pathway Responsible for Epigenetic Memory During Breast Cancer Progression
Researchers have determined how the TGF(beta)-Smad signaling pathway, which is over activated in late-stage cancers, is responsible for the “epigenetic memory” that maintains unique patterns of regulatory DNA hypermethylation causing silencing of critical genes that facilitate breast cancer progression. [Boston University School of Medicine, Boston]

Genes Linked to Breast Cancer Drug Resistance
Researchers have discovered a “gene activity signature” that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. [Dana-Farber Cancer Institute, Boston]

MammoCultBreastCancer_645x110_v01



CURRENT PUBLICATIONS

LABORATORY RESEARCH

Amplification of LAPTM4B and YWHAZ Contributes to Chemotherapy Resistance and Recurrence of Breast Cancer
By using integrated genomics, researchers identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. [Nat Med]

Synergistic Antitumor Effects of Combined Cathepsin B and Cathepsin Z Deficiencies on Breast Cancer Progression and Metastasis in Mice
Researchers conclude that the double deficiency of cathepsin Z and cathepsin B exerts exerts significant synergistic anticancer effects, whereas the single deficiencies demonstrate at least partial reciprocal compensation. [PNAS]

The Transcription Factor GATA-1 is Overexpressed in Breast Carcinomas and Contributes to Survivin Upregulation Via a Promoter Polymorphism
Breast cancer patients harbouring a polymorphism G235A in the survivin promoter present a higher level of survivin expression. [Oncogene]

Knock in of the AKT1 E17K Mutation in Human Breast Epithelial Cells Does Not Recapitulate Oncogenic PIK3CA Mutations
Researchers create a physiologic in vitro model to study the effects of the oncogenic mutation (G49A:E17K) in the AKT1 gene, by using somatic cell gene targeting using the nontumorigenic human breast epithelial cell line, MCF10A. [Oncogene]

PI3K Pathway Activation in Breast Cancer is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality
This study concluded that >70% of breast cancers have an alteration in at least 1 component of the PI3K pathway and this might be exploited to therapeutic advantage especially in  basal-like cancers. [Int J Cancer]

CLINICAL RESEARCH

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Single-agent cisplatin induced response in a subset of patients with triple-negative breast cancer (TNBC). Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. [J Clin Oncol]

MammaryCytokines_645x110_v01  


INDUSTRY NEWS

Medifocus, Inc. Announces Food and Drug Administration (FDA) Update for its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer: Files Response to Two Remaining Questions
Medifocus, Inc. announced that it has filed its response to two remaining questions with the Food and Drug Administration in the United States of America (USA) to obtain clearance to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer in the USA and worldwide. [Businesswire Press Release]

OncoVista Subsidiary Inks Exclusive Agreement with TATAA Molecular Diagnostics
OncoVista Innovative Therapies, Inc. announced that its wholly owned subsidiary, AdnaGen AG has entered into an agreement with TATAA Molecular Diagnostics, for the exclusive use of its Adnatest™ BreastCancer assays in an international breast cancer research COHERTA project. [Businesswire Press Release]


POLICY NEWS

Advisory Committees; Tentative Schedule of Meetings for 2010 [Food and Drug Administration, United States]

Clarification of SF424 (R&R) Application Instructions for Resubmissions of Revision and Renewal Applications (NOT-OD-10-052) [National Institutes of Health, United States]

NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD-PhD programs (F31) (PAR-10-091) [National Institutes of Health, United States]

Notice of Availability of Administrative Supplements for Activities to Promote Research Collaborations for Projects Currently Funded by the NCI Division of Cancer Biology (NOT-CA-10-015) [National Cancer Institute, United States]

Participation of NCCAM on RFA-OD-10-009, Recovery Act Limited Competition: Methodology Development in Comparative Effectiveness Research (RC4) (NOT-AT-10-001) [National Center for Complementary and Alternative Medicine, United States]



EVENTS

27th Annual Miami Breast Cancer Conference
March 3-6, 2010
Miami, United States

7th European Breast Cancer Conference
March 24-27, 2010
Barcelona, Spain

ASBD’s 34th Annual Symposium
April 16-17, 2010,
New York City, Untied States

BIT’s 3rd Annual World Cancer Congress 2010 – Breast Cancer Conference
April 25-27, 2010
Shanghai, China

IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

ASCO Annual Meeting
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES


Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

 

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us